Multiple sclerosis (DMTs)
multiple-sclerosis · society: AAN
Summary
AAN 2018 guideline on disease-modifying therapy (DMT) for adults with multiple sclerosis, replacing the 2002 AAN DMT guideline. Thirty consensus recommendations address starting (17), switching (10), and stopping (3) DMTs across RRMS, SPMS, PPMS, and clinically isolated syndrome (CIS), emphasizing shared decision-making, adherence, comorbidity management, and PML risk counseling. Ocrelizumab is endorsed for ambulatory PPMS, and specific guidance is given for natalizumab JCV-antibody risk stratification and pregnancy-related DMT decisions.
Current guideline: AAN 2018 MS Disease-Modifying Therapy Guideline · 
download Anki sub-deck
Versions
- 2018 · AAN — AAN 2018 MS Disease-Modifying Therapy Guideline